- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Advances and perspectives of PARP inhibitors ; volume:8 ; number:1 ; day:11 ; month:11 ; year:2019 ; pages:1-12 ; date:12.2019
Experimental hematology & oncology ; 8, Heft 1 (11.11.2019), 1-12, 12.2019
- Urheber
-
Yi, Ming
Dong, Bing
Qin, Shuang
Chu, Qian
Wu, Kongming
Luo, Suxia
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-019-0154-9
- URN
-
urn:nbn:de:101:1-2020030821432146306555
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.20252025, 01:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yi, Ming
- Dong, Bing
- Qin, Shuang
- Chu, Qian
- Wu, Kongming
- Luo, Suxia
- SpringerLink (Online service)
Ähnliche Objekte (12)
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors: current status and implications for anticancer therapeutics
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors: current status and implications for anticancer therapeutics
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors: current status and implications for anticancer therapeutics
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer